Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 May;89(5):357-60.
doi: 10.1016/j.contraception.2014.01.017. Epub 2014 Feb 1.

A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females

Andrea E Bonny  1 , Hannah L H Lange  2 , Lynette K Rogers  3 , Dave M Gothard  4 , Michael D Reed  5
Affiliations
Clinical Trial

A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females

Andrea E Bonny et al. Contraception. 2014 May.

Abstract

Objective: To explore the relationship between medroxyprogesterone acetate (MPA) pharmacokinetic (PK) parameter estimates and weight gain.

Study design: Prospective study of adolescents (N=40; age 12-21 years) initiating DMPA. PK parameters were calculated: maximum MPA concentration (Cmax, ng/mL), time to Cmax (Tmax, days) and elimination rate constant (ng/mL/day). Optimal PK cut points were determined for predicting body mass index (BMI) increase ≥10%.

Results: Cmax <2.88 ng/mL and elimination rate constant <0.021 ng/mL/day were associated (p<.05) with BMI increase ≥10%. Elimination rate constant was most predictive of weight gain.

Conclusions: PK evaluation may help identify adolescents at risk of excessive DMPA-associated weight gain.

Keywords: Adolescence; Contraception; Depo Provera; Pharmacokinetics; Weight.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest/Financial Disclosure: None.

Figures

Figure 1
Figure 1
Composite MPA concentration time curves (95% confidence intervals)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med. 2006;160:40–5. - PubMed
    1. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health. 1999;24:433–6. - PubMed
    1. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002;15:79–82. - PubMed
    1. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab. 1977;44:32–8. - PubMed
    1. Smit J, Botha J, McFadyen L, Beksinska M. Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval. Contraception. 2004;69:3–7. - PubMed

Publication types

Substances

LinkOut - more resources